A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Cancer Biology Bookmark and Share

Cancer Biology

City of Hope's Department of Cancer Biology offers a multidisciplinary research and training environment in a number of scientific areas, including:
 
  • Biomedical Informatics
  • Cancer Metabolism
  • Cancer Prevention and Diagnosis
  • Developmental Biology
  • Drug Resistance
  • Epigenetics
  • Hormonal Carcinogenesis
  • Genetics
  • Genomics
  • Tumor Biology

 

The department focuses on understanding the basic mechanisms of genetics, gene expression and function, signaling pathways, mutagenesis, DNA repair and epigenetics as they relate to the development and progression of cancer. Researchers within the department collaborate with clinical and basic research programs within City of Hope and with other research centers nationally and internationally. The research team explores mechanisms of cancer development (known as carcinogenesis) and aim to develop powerful approaches to cancer prevention and to improve diagnostic tools for detecting cancer early, when it is most treatable.


Laboratory Research

Shiuan Chen, Ph.D. – Chair and Professor - Hormones and Cancer: Chemoprevention
Dr. Chen has studied the role of aromatase in breast cancer development for more than 20 years. Currently Dr. Chen's research explores the mechanisms of endocrine resistance in breast cancer cells and seeks to understand the structure-function relationship of the aromatase protein in order to develop chemoprevention strategies using phytochemicals with anti-aromatase activity. His laboratory also investigates the impact of environmental chemicals on human health by modulating aromatase activity and expression.
 
WenYong Chen, Ph.D.Associate Professor - Epigenetics, Cancer and Aging
Dr. Chen's lab deciphers roles and functions of epigenetic regulators and determines their differential contribution to cancer and longevity, and through which, to develop approaches to improve cancer treatment, reduce cancer risk and promote healthy aging.
 
Gerald Holmquist, Ph.D. - Professor Emeritus
 
Jeremy Jones, Ph.D. Assistant Professor - Translational research in Urologic Oncology
Dr. Jones lab focuses on translational research in Urologic Oncology, identifying drug targets and developing treatments for prostate and kidney cancer.
 
Susan Kane, Ph.D.   – Professor Emeritus - Drug Resistance
Dr. Kane’s lab studies the molecular and cellular mechanisms of drug resistance to learn more about the mechanism of action why treatments fail and which patients will best respond to specific therapies.
 
Mei Kong, Ph.D. – Assistant Professor - Signal Transduction and Cancer Metabolism
Dr. Kong's research lab aims to delineate the strategies used by tumor cells to survive periods of metabolic stress and then to develop novel therapies targeting nutrient sensing pathways of neoplastic cells. Currently their research focuses on protein phosphatase 2A (PP2A) complexes in regulation of cancer cell survival upon nutrients deprivation.
 
Edward Newman, Ph.D. – Associate Professor - Development of novel DNA methyltransferase inhibitors for cancer therapy. Co-leader, Development Cancer Therapeutics Program
Dr. Newman's research concentrates on developing novel DNA methyltransferase inhibitors for cancer therapy.
 
Timothy O'Connor, Ph.D. – Associate Chair and Professor - DNA repair, mutagenesis and cancer
Dr. O'Connor's lab is interested in DNA repair mechanisms, the biological consequences of repair failure, exploiting DNA repair mechanisms for therapeutic benefit and how DNA repair mechanisms can be used to control the epigenome of cells.
 
Arthur Riggs, Ph.D. – Adjunct Professor (Chairperson-Diabetes and Director Emeritus, Beckman Research Institute) - DNA Methylation and Mammalian Gene Regulation
Dr. Riggs' lab research is broad-based and encompasses chromatin structure-function and gene regulation. Current studies include epigenetic changes in early mouse development, including demethylation mechanisms.
 
Judith Singer-Sam, Ph.D. – Professor Emeritus - Epigenetics and Developmental Biology
Monoallelic expression is a characteristic of genes that are implicated in certain inherited disorders of the CNS as well as some cancers. Using clonal CNS-derived neural stem cells as a model system, Dr. Sam's group is studying possible mechanisms for such expression.
 
Timothy W. Synold, Pharm. D.Professor;  Director, Analytical Pharmacology Core Facility and Director, Clinical Immunobiology Correlative Studies Laboratory
Dr. Synold has been actively investigating the pharmacokinetics and pharmacodynamics of anticancer agents for nearly 25 years. His current research is focused on the blood-brain-brain barrier and its impact on drug delivery to the CNS. Dr. Synold also participates in many of the drug development efforts of City of Hope Cancer Center members, and is Director of the Analytical Pharmacology Core Facility and the Clinical Immunobiology Correlative Studies Laboratory.
 
S. Emily Wang, Ph.D. – Associate Professor - Growth Factors and Cancer
Dr. Wang's group focuses on the role of signaling by growth factor receptors and oncogenes in cancer progression as well as the development of molecular therapeutics based on mechanistic study.
 

Cancer Biology Faculty

Cancer Biology

Cancer Biology

City of Hope's Department of Cancer Biology offers a multidisciplinary research and training environment in a number of scientific areas, including:
 
  • Biomedical Informatics
  • Cancer Metabolism
  • Cancer Prevention and Diagnosis
  • Developmental Biology
  • Drug Resistance
  • Epigenetics
  • Hormonal Carcinogenesis
  • Genetics
  • Genomics
  • Tumor Biology

 

The department focuses on understanding the basic mechanisms of genetics, gene expression and function, signaling pathways, mutagenesis, DNA repair and epigenetics as they relate to the development and progression of cancer. Researchers within the department collaborate with clinical and basic research programs within City of Hope and with other research centers nationally and internationally. The research team explores mechanisms of cancer development (known as carcinogenesis) and aim to develop powerful approaches to cancer prevention and to improve diagnostic tools for detecting cancer early, when it is most treatable.


Laboratory Research

Shiuan Chen, Ph.D. – Chair and Professor - Hormones and Cancer: Chemoprevention
Dr. Chen has studied the role of aromatase in breast cancer development for more than 20 years. Currently Dr. Chen's research explores the mechanisms of endocrine resistance in breast cancer cells and seeks to understand the structure-function relationship of the aromatase protein in order to develop chemoprevention strategies using phytochemicals with anti-aromatase activity. His laboratory also investigates the impact of environmental chemicals on human health by modulating aromatase activity and expression.
 
WenYong Chen, Ph.D.Associate Professor - Epigenetics, Cancer and Aging
Dr. Chen's lab deciphers roles and functions of epigenetic regulators and determines their differential contribution to cancer and longevity, and through which, to develop approaches to improve cancer treatment, reduce cancer risk and promote healthy aging.
 
Gerald Holmquist, Ph.D. - Professor Emeritus
 
Jeremy Jones, Ph.D. Assistant Professor - Translational research in Urologic Oncology
Dr. Jones lab focuses on translational research in Urologic Oncology, identifying drug targets and developing treatments for prostate and kidney cancer.
 
Susan Kane, Ph.D.   – Professor Emeritus - Drug Resistance
Dr. Kane’s lab studies the molecular and cellular mechanisms of drug resistance to learn more about the mechanism of action why treatments fail and which patients will best respond to specific therapies.
 
Mei Kong, Ph.D. – Assistant Professor - Signal Transduction and Cancer Metabolism
Dr. Kong's research lab aims to delineate the strategies used by tumor cells to survive periods of metabolic stress and then to develop novel therapies targeting nutrient sensing pathways of neoplastic cells. Currently their research focuses on protein phosphatase 2A (PP2A) complexes in regulation of cancer cell survival upon nutrients deprivation.
 
Edward Newman, Ph.D. – Associate Professor - Development of novel DNA methyltransferase inhibitors for cancer therapy. Co-leader, Development Cancer Therapeutics Program
Dr. Newman's research concentrates on developing novel DNA methyltransferase inhibitors for cancer therapy.
 
Timothy O'Connor, Ph.D. – Associate Chair and Professor - DNA repair, mutagenesis and cancer
Dr. O'Connor's lab is interested in DNA repair mechanisms, the biological consequences of repair failure, exploiting DNA repair mechanisms for therapeutic benefit and how DNA repair mechanisms can be used to control the epigenome of cells.
 
Arthur Riggs, Ph.D. – Adjunct Professor (Chairperson-Diabetes and Director Emeritus, Beckman Research Institute) - DNA Methylation and Mammalian Gene Regulation
Dr. Riggs' lab research is broad-based and encompasses chromatin structure-function and gene regulation. Current studies include epigenetic changes in early mouse development, including demethylation mechanisms.
 
Judith Singer-Sam, Ph.D. – Professor Emeritus - Epigenetics and Developmental Biology
Monoallelic expression is a characteristic of genes that are implicated in certain inherited disorders of the CNS as well as some cancers. Using clonal CNS-derived neural stem cells as a model system, Dr. Sam's group is studying possible mechanisms for such expression.
 
Timothy W. Synold, Pharm. D.Professor;  Director, Analytical Pharmacology Core Facility and Director, Clinical Immunobiology Correlative Studies Laboratory
Dr. Synold has been actively investigating the pharmacokinetics and pharmacodynamics of anticancer agents for nearly 25 years. His current research is focused on the blood-brain-brain barrier and its impact on drug delivery to the CNS. Dr. Synold also participates in many of the drug development efforts of City of Hope Cancer Center members, and is Director of the Analytical Pharmacology Core Facility and the Clinical Immunobiology Correlative Studies Laboratory.
 
S. Emily Wang, Ph.D. – Associate Professor - Growth Factors and Cancer
Dr. Wang's group focuses on the role of signaling by growth factor receptors and oncogenes in cancer progression as well as the development of molecular therapeutics based on mechanistic study.
 

Cancer Biology Faculty

Cancer Biology Faculty

Overview
Beckman Research Institute of City of Hope is responsible for fundamentally expanding the world’s understanding of how biology affects diseases such as cancer, HIV/AIDS and diabetes.
 
 
Research Departments/Divisions

City of Hope is a leader in translational research - integrating basic science, clinical research and patient care.
 

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

City of Hope’s Irell & Manella Graduate School of Biological Sciences equips students with the skills and strategies to transform the future of modern medicine.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 


NEWS & UPDATES
  • White button mushrooms seem fairly innocuous as fungi go. Unlike portabellas, they don’t center stage at the dinner table, and unlike truffles, they’re not the subject of gourmand fervor. But appearances can be deceiving when it comes to these mild-mannered Clark Kents of the food world. In a study ...
  • Doctors often recommend preventive screenings for several cancers, based on hereditary or genetic factors, but brain tumors aren’t one of them. Primary brain tumors, which originate in the brain rather than spreading from another location, seem to develop at random, and doctors have little insight into wh...
  • Stopping cancer starts with research. To that end, STOP CANCER has awarded $525,000 in grants to City of Hope for 2015, supporting innovative research projects and recognizing the institution’s leadership in advancing cancer treatment and prevention. Founded in 1988, STOP CANCER underwrites the work of le...
  • Cancer may not be the disease many people think it is. Normally, cancer is considered to be a disease in which cells multiply at an extremely high, and unusual, rate – increasing the likelihood of genetic mutations. But increasingly, leading researchers at City of Hope and elsewhere are contending that cancer i...
  • “Of all forms of inequality, injustice in the health care system is the most shocking and inhumane.” By the time the Rev. Martin Luther King Jr. spoke those words in Chicago in 1966, the Civil Rights Act had been passed, the Voting Rights Act was the law of the land and the March on Washington was […]
  • Eight years ago, Matthew Loscalzo surprised himself by accepting the offer to become City of Hope’s administrative director of the Sheri & Les Biller Patient and Family Resource Center and executive director of the Department of Supportive Care Medicine. At the time, he was administrative director of the Sc...
  • The mental fog that patients can experience after undergoing chemotherapy treatment for cancer has a name: “chemo brain.” “Many patients report hearing or reading about chemotherapy-related cognitive deficits, but few are actually prepared to deal with these changes,” said Celina Lemon, M.A., an occupational th...
  • Cancer treatments have improved over the years, but one potential source of treatments and cures remains largely untapped: nature. Blueberries, cinnamon, xinfeng, grape seed (and skin) extract, mushrooms, barberry and pomegranates all contain compounds with the potential to treat or prevent cancer. Scientists a...
  • In the U.S., there are more new cases of skin cancer than the combined incidence of cancers of the breast, prostate and lung, according to the American Cancer Society. Each year, 5 million people are treated for skin cancer. Here, Hans Schoellhammer, M.D., assistant clinical professor at City of Hope | Ant...
  • As public health experts know, health improvement starts in the community. Now, City of Hope  has been recognized for its efforts to improve the lives of residents of its own community. The institution will receive funding from the Institute for Healthcare Improvement  to support promising community-based work ...
  • For almost four decades, blood cancer survivors who received bone marrow, or stem cell, transplants have returned to City of Hope to celebrate life, second chances and science. The first reunion, in 1976, was a small affair: spaghetti for a single patient, his brother who served as his donor and those who took ...
  • Chemotherapy is an often-essential component of cancer treatment, attacking cells that divide quickly and helping stop cancer’s advance. But the very characteristics that make chemotherapy effective against cancer also can make it toxic to healthy cells, leading to side effects such as hair loss, nausea, ...
  • When you want to understand how to enhance the patient experience, go straight to the source: The patients. Patients and their families offer unique perspectives on care and services and can provide valuable insights about what is working well and what is not. That’s why City of Hope turns to them for advice. S...
  • Take it from City of Hope researchers: Medical science isn’t just for scientists, but something the whole family can enjoy. From 1 to 4 p.m. on Saturday, May 16, the institution will offer a variety of educational and fun-filled science and healthy living activities at its second Community Science Festiva...
  • Attention, parents! Only a few serious sunburns can increase a child’s ultimate risk of skin cancer. Further, some studies suggest that ultraviolet (UV) exposure before the age of 10 is the most important factor for melanoma risk. Here skin cancer expert Jae Jung, M.D., Ph.D., assistant professor in the D...